BRPI0414175A - método melhorado de tratamento de distúrbios do crescimento - Google Patents
método melhorado de tratamento de distúrbios do crescimentoInfo
- Publication number
- BRPI0414175A BRPI0414175A BRPI0414175-0A BRPI0414175A BRPI0414175A BR PI0414175 A BRPI0414175 A BR PI0414175A BR PI0414175 A BRPI0414175 A BR PI0414175A BR PI0414175 A BRPI0414175 A BR PI0414175A
- Authority
- BR
- Brazil
- Prior art keywords
- improved method
- treatment
- growth hormone
- growth
- growth disorders
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 5
- 208000037824 growth disorder Diseases 0.000 title abstract 3
- 102000018997 Growth Hormone Human genes 0.000 abstract 3
- 108010051696 Growth Hormone Proteins 0.000 abstract 3
- 239000000122 growth hormone Substances 0.000 abstract 3
- 230000002411 adverse Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 235000021588 free fatty acids Nutrition 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/27—Growth hormone [GH], i.e. somatotropin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Physical Education & Sports Medicine (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Gastroenterology & Hepatology (AREA)
- Psychiatry (AREA)
- Zoology (AREA)
- Reproductive Health (AREA)
- Emergency Medicine (AREA)
- Virology (AREA)
- Gynecology & Obstetrics (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
Abstract
"MéTODO MELHORADO DE TRATAMENTO DE DISTúRBIOS DO CRESCIMENTO". A presente invenção refere-se a um tratamento de condições e doenças para as quais o hormónio do crescimento é um método de tratamento desejável, utilizando reguladores de ácidos graxos livres em associação com hormónio do crescimento. Em particular, a presente invenção descreve um método melhorado de tratamento de alterações do crescimento bem como métodos para impedir e/ou reduzir as conseqüências adversas do tratamento com hormónio do crescimento.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
NZ52838803 | 2003-09-19 | ||
PCT/IB2004/003063 WO2005027894A1 (en) | 2003-09-19 | 2004-09-14 | Enhanced method of treatment of growth disorders |
Publications (1)
Publication Number | Publication Date |
---|---|
BRPI0414175A true BRPI0414175A (pt) | 2006-10-31 |
Family
ID=34374472
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0414175-0A BRPI0414175A (pt) | 2003-09-19 | 2004-09-14 | método melhorado de tratamento de distúrbios do crescimento |
Country Status (8)
Country | Link |
---|---|
US (1) | US20070037861A1 (pt) |
EP (1) | EP1667671A1 (pt) |
JP (1) | JP2007505892A (pt) |
AR (1) | AR045766A1 (pt) |
BR (1) | BRPI0414175A (pt) |
CA (1) | CA2538846A1 (pt) |
TW (1) | TW200512003A (pt) |
WO (1) | WO2005027894A1 (pt) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2059260B1 (en) * | 2006-08-31 | 2013-06-19 | Novartis AG | Pharmaceutical compositions comprising hGH for oral delivery |
WO2012104838A1 (en) * | 2011-02-01 | 2012-08-09 | Mor Researchr Applications Ltd. | Use of hgh for the treatment of small for gestational age infants under two years of age |
PL2988617T3 (pl) | 2013-03-27 | 2024-02-19 | Nutritional Growth Solutions Ltd | Suplement odżywczy do poprawy wzrostu |
PL3352752T3 (pl) * | 2015-09-21 | 2022-04-19 | Lumos Pharma Inc. | Wykrywanie i leczenie niedoboru hormonu wzrostu |
CN108882745B (zh) | 2016-03-10 | 2023-08-18 | 花臣有限公司 | 脂质组合物及其用途 |
BR112021015799A2 (pt) | 2019-02-12 | 2022-01-18 | Mirum Pharmaceuticals Inc | Métodos para aumentar o crescimento em pacientes pediátricos com doença colestática do fígado |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1149583A3 (en) * | 2000-04-13 | 2001-11-14 | Pfizer Products Inc. | Combinations of corticotropin releasing factor antagonists and growth hormone secretagogues |
IL145106A0 (en) * | 2000-08-30 | 2002-06-30 | Pfizer Prod Inc | Intermittent administration of a geowth hormone secretagogue |
-
2004
- 2004-09-14 WO PCT/IB2004/003063 patent/WO2005027894A1/en not_active Application Discontinuation
- 2004-09-14 US US10/572,699 patent/US20070037861A1/en not_active Abandoned
- 2004-09-14 EP EP04769431A patent/EP1667671A1/en not_active Withdrawn
- 2004-09-14 CA CA002538846A patent/CA2538846A1/en not_active Abandoned
- 2004-09-14 BR BRPI0414175-0A patent/BRPI0414175A/pt not_active IP Right Cessation
- 2004-09-14 JP JP2006526732A patent/JP2007505892A/ja active Pending
- 2004-09-16 TW TW093128039A patent/TW200512003A/zh unknown
- 2004-09-17 AR ARP040103364A patent/AR045766A1/es unknown
Also Published As
Publication number | Publication date |
---|---|
CA2538846A1 (en) | 2005-03-31 |
WO2005027894A1 (en) | 2005-03-31 |
AR045766A1 (es) | 2005-11-09 |
TW200512003A (en) | 2005-04-01 |
JP2007505892A (ja) | 2007-03-15 |
US20070037861A1 (en) | 2007-02-15 |
EP1667671A1 (en) | 2006-06-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL219857A0 (en) | Mitotic kinesin inhibitors, pharmaceutical compositions comprising them, uses thereof in the manufacture of a medicament for the treatment of disease or disorder in a human or animal that can be treated by inhibiting mitosis | |
MY151018A (en) | Use of nutritional compositions for preventing disorders | |
WO2009044271A3 (en) | Systems and methods for treatment of medical conditions related to the central nervous system and for enhancing cognitive functions | |
BRPI0713442A2 (pt) | Método para o tratamento de desrodens neurológicas, pelo aumento da atividade de b-glicocerebrosidase | |
MY176679A (en) | Use of nutritional compositions for preventing disorders | |
WO2007130474A3 (en) | Method of differentiating stem cells into cells of the endoderm and pancreatic lineage | |
MX2010004074A (es) | Combinacion 059. | |
WO2007090144A3 (en) | System and methods for the treatment of retinal diseases | |
MX2007012794A (es) | Composiciones para el tratamiento de trastornos del tejido conectivo de la piel. | |
PH12016500715A1 (en) | Di-isopropyl-phosphinoyl-alkane (dapa) compounds as topical agents for the treatment of sensory discomfort | |
EP2633052A4 (en) | TREATMENT OF DISEASES ASSOCIATED WITH THE INTERFERON 1-RELATED DEVELOPMENT REGULATOR (IFRD1) BY INHIBITING THE NATURAL ANTISENSE TRANSCRIPTION PRODUCT OF IFRD1 | |
BR0317888A (pt) | Cristais do hormÈnio do crescimento humano e processos para preparação dos mesmos | |
WO2003092617A3 (en) | Combinations for the treatment of inflammatory skin disorders | |
HK1092358A1 (en) | Method for producing medicaments for reducing amyloid deposition, amyloid neurotoxicity and microgloisis | |
WO2008157787A3 (en) | Hydroxylated tolans and related compounds in the treatment of cancer | |
BRPI0414175A (pt) | método melhorado de tratamento de distúrbios do crescimento | |
BR0306855A (pt) | Método para o tratamento de distúrbios cognitivos | |
WO2003057162A3 (en) | Combination for the treatment of immunoinflammatory disorders and proliferative skin diseases | |
BR112022021964A2 (pt) | Ácidos nucleicos modificados que codificam aspartoacilase (aspa) e vetores para terapia gênica | |
BR112022020924A2 (pt) | Métodos de tratamento de um transtorno do sono, a sonolência diurna em um indivíduo, a insônia, e, daridorexante na forma de sal livre ou farmaceuticamente aceitável | |
MX2009004962A (es) | Metodo para tratar asma, rinitis alergia y trastornos de la piel. | |
ATE345121T1 (de) | Verwendung von konjugierter linolsäure zur behandlung der erkältung | |
UA91136C2 (ru) | Системы, фармацевтическая композиция на его основе и способ ее применения | |
WO2013003801A3 (en) | Inhibitor of neuronal connectivity linked to schizophrenia susceptibility and cognitive dysfunction | |
Feifei et al. | The effect of transcranial direct current stimulation on memory function |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 4A,5A,6A E 7A ANUIDADE(S) |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2129 DE 25/10/2011. |